Study of PLGA-Mg Material in Clinical Orthopedics

NCT ID: NCT03060655

Last Updated: 2017-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The different proportion samples of PLGA-Mg were made in this study. Then, they would be placed in the femoral condyle of the New Zealand rabbits. The appropriate proportion of PLGA-Mg is obtained after the experiment, which will be used to make the plate or screw to fix the fragments. Then, the clinical role for bone will be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The deposition of calcium could be facilitated by the increase of magnesium, which played an important role in fracture union. However, its degradation may be completed before the fracture line was disappeared. In addition, the hydrogen may be released during degradation. Thus, its clinical popularization was limited.

As a new polymer material, poly lactic-co-glycolic acid (PLGA) has been widely used clinically. The hydrolytic production of PLGA was acidic, which could neutralize the alkalinity of production degraded from magnesium. In addition, it was a long time before the total accomplishment of degradation of PLGA, which may postpone the degradation of magnesium.

The different proportion samples of PLGA-Mg were made in this study. Their physical and chemical properties were analyzed to estimate its safety of implantation. Then, they would be placed in the femoral condyle of the New Zealand rabbits. The osteogenesis and complication of samples are examined to select an appropriate proportion of PLGA-Mg is obtained. Then, the PLGA-Mg material will be used to fix the fracture of human as a fixation. The review of the patients will be conducted to assess its clinical role.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fracture Dislocation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PLGA-Mg material

The fixation of fragments of study group was accomplished with PLGA-Mg material.

Group Type PLACEBO_COMPARATOR

PLGA-Mg material

Intervention Type BIOLOGICAL

The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.

titanium alloy

The fixation of fragments of control group was accomplished with titanium alloy material.

Group Type PLACEBO_COMPARATOR

titanium alloy

Intervention Type BIOLOGICAL

Traditional fixation was titanium alloy. the clinical outcome was assessed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PLGA-Mg material

The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.

Intervention Type BIOLOGICAL

titanium alloy

Traditional fixation was titanium alloy. the clinical outcome was assessed.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-65 years old
* Closed fracture
* Sign the agreement of the experiment

Exclusion Criteria

* Pathologic fracture
* Open fracture
* Refused to participate
* Follow-up insufficient 12 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hebei Medical University Third Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ruipeng Zhang, M.D

Role: PRINCIPAL_INVESTIGATOR

Third Hospital of Hebei Medical University Department of Orthopaedic Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hebei Medical University Third Hospital

Shijiazhuang, Hebei, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yingze Zhang, M.D

Role: CONTACT

+8613313012888

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yingze Zhang, M.D

Role: primary

+8613313012888

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZYZ2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Surgery of the Pilon Fractures
NCT03367169 TERMINATED NA